ImmunoPrecise Antibodies announces AI-driven breakthrough in dengue vaccine

ImmunoPrecise Antibodies (IPA) announced discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai platform powered by their patented Hyft technology. This discovery, made using several proprietary HYFT-based analyses, identifies a part of the virus that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. The company said. “This discovery marks a major milestone toward the development of a potential universal dengue vaccine and validates the Company’s newly launched, HYFT pattern-patented AI-native vaccine discovery engine. Building on this success in dengue, IPA now intends to extend its AI-driven vaccine design platform to other high-impact infectious diseases, for example, HIV, Norovirus, and an improved RSV vaccine. Early-stage assessments are also underway to explore the platform’s application in oncology for neoantigen vaccine development and tumor-specific epitope mapping.”